Re-Vana Therapeutics is an ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma.
Our delivery platforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using our platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 4-6 months or more.
Our injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 4-6 months or more. Our preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 4-6 months or more.
The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.
Check back for opportunities.
EyeLief™ is a novel photocrosslinked sustained-release preformed biodegradable implant delivering large and small therapeutics for 4-6 months or more.